Introduction
============

Overactive bladder (OAB) is a common condition characterized by urinary urgency, with or without urge incontinence usually with frequency and nocturia ([@b1-cia-1-309]). Epidemiological studies from the US have reported the prevalence of OAB to be 16.9% ([@b36-cia-1-309]); it can affect men and women alike, but the prevalence increases with age. OAB can have a detrimental effect on physical functioning and psychological well-being, as well as significantly reducing quality of life ([@b2-cia-1-309]). In patients under 25 the prevalence is 4.8% and in those over the age of 65 years 30.9% ([@b24-cia-1-309]; [@b36-cia-1-309]). In the elderly the commonest manifestation is urinary incontinence ([@b7-cia-1-309]).

Antimuscarinic drug therapy, in conjunction with behavioral therapy such as bladder retraining, remains the first line of management in patients with irritative bladder symptoms or OAB. Several antimuscarinic agents are currently available for the treatment of OAB in adults. The antimuscarinics all appear to exert their clinical effect through inhibition of the bladder muscarinic receptors, but they vary in their functional profile and can be associated with troublesome side effects such as dry mouth, constipation, somnolence, and blurred vision. In a questionnaire follow-up study of women with detrusor overactivity, just 5.5% were cured of their urinary symptoms and only 18.2% of women continued drug therapy for more than 6 months ([@b20-cia-1-309]). The development of relatively bladder selective antimuscarinic drugs such as tolterodine has helped to reduce adverse effects, but the development of darifenacin and the recent marketing of solifenacin represent the first highly selective bladder specific anti-muscarinic (M~3~ specific antimuscarinics) agents for the management of OAB.

While efficacy of antimuscarinics has been demonstrated in adult populations (including patients \>65 years of age), few studies have been reported specifically in a geriatric population, and antimuscarinics are often underutilized in the elderly despite the marked increase in the prevalence of OAB in this age group. One explanation for this apparent under-use of an effective treatment option may be concerns about the frequency of anticholinergic adverse events, such as dry mouth; the likelihood of detrimental central nervous system (CNS) effects, including cognitive impairment and sleep disturbances; and the potential for harmful interactions with existing pharmacotherapy.

Muscarinic receptors and effects of aging
=========================================

Molecular cloning studies have revealed the existence of five genes for muscarinic receptors in rats and humans. This corresponds to five subtypes of muscarinic receptors, M~1~--M~5~ ([@b8-cia-1-309]). The distribution of the different subtypes in the human body varies and so does their functional importance. Table [1](#t1-cia-1-309){ref-type="table"} shows the distribution of different muscarinic receptors in the body.

Detrusor muscle from various species including man contains M~2~ and M~3~ receptors. Although the M~2~ receptors predominate (approximately M~2~:M~3~:2:1), in humans it is the M~3~ receptors that are thought to cause a direct muscle contraction via phosphoinositide hydrolysis ([@b18-cia-1-309]), whereas M~1~ receptors have never been demonstrated ([@b41-cia-1-309]). It is thought that the M~3~ receptor is responsible for the normal micturition contraction (Caulfield and Birdsall 1996). The M~2~ receptors may become more important in mediating detrusor contractions in certain disease states such as neurogenic bladder dysfunction ([@b5-cia-1-309]).

Animal studies show there is no change in the relative abundance of M~2~ and M~3~ receptors with advancing age; this is accompanied by only minor if any alterations in receptor responsiveness ([@b31-cia-1-309]).

Pharmacology: darifenacin
=========================

Darifenacin is a highly specific M~3~ receptor antagonist which is used in the US and Europe, and is yet to be launched in the UK. It has been shown to have a higher degree of selectivity for the M~3~ receptors (Tables [2](#t2-cia-1-309){ref-type="table"} and [3](#t3-cia-1-309){ref-type="table"}) than the commonly used antimuscarinics currently available and has activity both in vitro ([@b38-cia-1-309]) and in vivo ([@b29-cia-1-309]). It may be expected that drugs selective for the M~3~ receptors in the bladder have greater clinical efficacy in detrusor overactivity. It has also been shown to have a reduced adverse side effect profile ([@b3-cia-1-309]).

Darifenacin was acquired by Novartis in May 2003 and is expected to be marketed as Enablex in the UK in the near future.

Effects in vivo
---------------

In bladder and salivation models of conscious rats, darifenacin has been compared with oxybutynin ([@b39-cia-1-309]). The micturition interval and volume as well as the peak micturition pressure were assessed before and an hour after injection with the test compound (darifenacin 0.1--0.3 mg/kg; oxybutynin 0.1--3.0 mg/kg). Dose-related decreases were seen in all micturition parameters, which were significantly greater than those seen with oxybutynin (p\<0.05), although the effect was equipotent on salivation.

Effects on CNS
--------------

The side effects of antimuscarinics on the CNS have been well documented. Adverse effects such as somnolence and cognitive impairment are a result of M~1~ blockade in the brain. The role of M~1~ receptors in cognitive function is well accepted, and is the basis of the therapeutic principle in the treatment of Alzheimer's disease ([@b3-cia-1-309]). The elderly therefore are particularly at risk of cognitive side effects with non-specific antimuscarinics hence the reluctance to use them in the elderly population.

To assess the effects of darifenacin controlled-release and oxybutynin extended-release (ER) on cognitive function (particularly memory) 150 patients ≥60 years old, were randomized to darifenacin, oxybutynin ER or placebo in a multicenter, double-blind, double-dummy, parallel-group, 3-week study ([@b19-cia-1-309]). Doses were administered according to US labels: oxybutynin ER 10 mg once daily (od), increasing to 15 mg od in weeks 1 and 2, then 15 mg od in week 3. The primary end point was accuracy on the Name-Face Association Test (delayed recall) at week 3. While darifenacin had no significant effects on memory versus placebo, oxybutynin ER caused significant memory deterioration (magnitude of effect comparable with brain aging of 10 years).

Similar studies in younger populations testing the effects of darifenacin on cognitive function at doses of 7.5 mg or 15 mg, did not produce any detectable effects relative to placebo ([@b26-cia-1-309]). The sparing of cognitive function in relation to the use of darifenacin (and trospium) is an attractive result of the M~1~-sparing effect of darifenacin and is therefore potentially very useful in the elderly.

Effects on the cardiovascular system and the electrocardiogram
--------------------------------------------------------------

A study in the chioralose--urethane anesthetized beagle dog assessed the potency of darifenacin, tolterodine, oxybutynin, and propiverine on pelvic nerve-stimulated bladder contractions, trigeminal nerve stimulated salivation, and heart rate ([@b15-cia-1-309]). Darifenacin did not increase the heart rate at doses required to maximally inhibit bladder contractility (100 μg/kg), whereas tolterodine increased heart rate at doses within the range needed to inhibit contractility. In the study by [@b26-cia-1-309], darifenacin (7.5 mg and 15 mg) had no significant effect on heart rate or heart rate variability, whereas dicyclomine (dicycloverine) significantly reduced heart rate (−4.79 bpm, p=0.003) and increased variability (12%, p=0.005) compared with placebo. No changes in either the vital signs or electrocardiogram (ECG) were found to be due to darifenacin. Prolongation of QT interval on an ECG is a valuable predictor of a drug's ability to cause potentially fatal ventricular tachyarrhythmia. [@b32-cia-1-309] found there was no significant increase in QT interval with darifenacin treatment compared with placebo.

Pharmacokinetics
----------------

The pharmacokinetics of darifenacin have been determined in human volunteers after oral administration of the drug and studied in animal models after oral and intravenous administration ([@b4-cia-1-309]). Pooled data have been used to model population pharmacokinetics ([@b22-cia-1-309]). Plasma concentrations were calculated using ([@b3-cia-1-309]) C-labelled darifenacin 5 mg dose, after 5 days of achieving a steady-state plasma concentration.

Darifenacin is well absorbed in humans. Unchanged darifenacin is present in very small amounts in the feces, showing that it is almost completely absorbed from the gastro-intestinal tract ([@b4-cia-1-309]). Compared with immediate release preparations, higher bioavailability has been noted with extended release preparations ([@b22-cia-1-309]). This may be due to differing activity of the metabolizing mechanisms in the lower intestinal tract ([@b28-cia-1-309]). Food has no effect on absorption ([@b26-cia-1-309]).

Darifenacin is highly protein-bound in the plasma (\>96% in all species tested; 98% in man) ([@b4-cia-1-309]). Volumes of distribution are higher than body water in the animal models after intravenous administration (12 L/kg, 7 L/kg, and 6.8 L/kg in mouse, rat, and dog, respectively).

Darifenacin has an efficient hepatic metabolism ([@b4-cia-1-309]) and this is demonstrated by plasma clearance values that are high relative to hepatic blood flow. This leads to a short half-life in man. Darifenacin has three principal mechanisms of metabolism: monohydroxylation in either the dihydrobenzfuran or diphenylacetamide moieties; opening of the dihydrobenzfuran ring; or N-dealkylation at the pyrrolidine nitrogen. The main metabolite, UK-148993 ([@b4-cia-1-309]), is formed primarily through hydroxylation of darifenacin by cytochrome P4503A4 (CYP3A4) and cytochrome P4502D6 (CYP2D6) and is 50-fold less potent than the parent drug ([@b21-cia-1-309]). There is a great deal of polymorphism in CYP2D6, and individuals with poor CYP2D6 metabolism may have higher plasma levels of the drug, with 20% reduction in clearance of the drug, and 52% increase in bioavailability ([@b22-cia-1-309]) when compared with homozygote extensive metabolizers. Japanese subjects have a 56% lower availability of darifenacin than Caucasians ([@b22-cia-1-309]). No other racial differences in bioavailability were seen, indicating that the difference is due to increased first pass metabolism in the liver (by CYP3A4 and CYP2D6). Distribution of alleles pertaining to CYP2D6 is known to differ between Japanese and Caucasian races ([@b40-cia-1-309]), but when the CYP2D6 activity was controlled for separately, and knowing that no ethnic differences seem to exist in CYP3A4 activity ([@b40-cia-1-309]), it appears that other as yet unidentified factors are involved. Women have a 31% lower rate of clearance of darifenacin than men ([@b22-cia-1-309]), which is felt to be due to a lower activity of CYP2D6 in women ([@b37-cia-1-309]) and which would seem therefore to draw parallels with the CYP2D6 poor-metabolizers previously alluded to (despite a higher activity of CYP3A4 in women \[[@b37-cia-1-309]\]). Biotransformation by the cytochrome P450 (CYP450) system is an important step in the activation or elimination of a large number of drugs, including oxybutynin, tolterodine, darifenacin, and solifenacin, raising the possibility of clinically relevant and potentially serious drug interactions. In elderly patients, such interactions are of particular relevance given the potential for declining activity of certain members of the CYP450 family combined with decreased hepatic blood flow, which can reduce first-pass metabolism and thus the bioavailability of drugs metabolized via this route.

After administration of 14C-labelled darifenacin, most of the radioactive dose was recovered within 48 h, balanced between urine and feces in humans ([@b4-cia-1-309]). Approximately 44% of a dose was recovered from the feces and 58% from the urine, in both cases predominantly as metabolites.

Drug interactions
-----------------

Data assessing drug and food interactions of darifenacin are relatively scarce. [@b22-cia-1-309] have looked at the effect of ketoconazole (an azole used in the treatment of fungal conditions) and erythromycin (a macrolide antibiotic) on the metabolism of darifenacin. Both of these agents are CYP3A4 inhibitors, although ketoconazole is 50 times more potent than erythromycin. Use of ketoconazole reduced clearance of darifenacin by 68% ([@b22-cia-1-309]) and increased the bioavailability of the drug to 100%. Erythromycin had no effect on clearance but increased bioavailability to 97%. Ketoconazole and erythromycin also affected levels of the active darifenacin metabolite, although this was thought to be due to a reduction in metabolism from the parent drug, rather than an increase in clearance of the metabolite.

Caution is therefore warranted in the use of darifenacin in patients taking CYP3A4 inhibitors. Potent inhibitors should be avoided in view of their combined effect on clearance and metabolism. Higher doses of darifenacin are generally well tolerated, and so modest increases in drug concentration with less potent inhibitors are not clinically relevant.

Efficacy studies
================

Darifenacin has been the subject of several well conducted and extensive trials with rigorous entry criteria. Analysis of pooled data from three such studies enrolled 1059 patients (85% of whom were female; age range 19--88 years) with at least 6-month history of overactive bladder symptoms (urgency, frequency, and urge incontinence) ([@b10-cia-1-309]). All had a 2-week washout and a 2-week placebo run-in, prior to commencing active participation. Participants were randomized to receive either darifenacin-controlled release 7.5 mg or matched placebo (n=335/271, respectively) or darifenacin controlled release 15 mg or matched placebo (n=330/384, respectively). Outcome data were collected by use of an electronic diary (hand-held computerized diaries have been developed to overcome the lack of patient compliance that has been noted in many studies \[[@b30-cia-1-309]\]; patients felt that their symptoms were more properly reflected by the computerized version, felt more motivated to provide data, and found it easier to remember to enter data).

Both doses of darifenacin were significantly superior to placebo in alleviating the symptoms associated with OAB (Table [4](#t4-cia-1-309){ref-type="table"}), however, a marked placebo response was noted. Darifenacin (15 mg controlled release) has also been compared with oxybutynin (5 mg TDS) and matched placebo ([@b42-cia-1-309]). Seventy-six patients (93% female) had detrusor overactivity (urodynamically verified OAB) with ≥4 urinary incontinence (UI) episodes per week and a frequency of \>8 micturitions per day; all underwent a 2-week run-in period prior to 2 weeks of treatment in each arm, in a randomized sequence. Outcomes were assessed using a paper diary (Table [5](#t5-cia-1-309){ref-type="table"}). The results revealed comparable efficacy with oxybutynin, in terms of significant improvement of the major symptoms of OAB, when compared with placebo.

Rapid onset of action of darifenacin is a useful attribute and has been assessed in a well conducted study ([@b16-cia-1-309]). In this study, 561 patients (age range 19--88 years; 85% female) were enrolled with OAB symptoms of more than 6-month duration. After a 2-week washout and a 2-week placebo run-in, the participants were randomized in a 1:4:2:3 ratio to 3.75 mg darifenacin, 7.5 mg darifenacin, 15 mg darifenacin, or placebo. Significant and rapid onset of action was noted by 2 weeks, although evolving benefit was seen up to 12 weeks in this study. Benefits to patients taking darifenacin have been shown, not only in terms of symptom improvement but also by demonstrable improvements in quality of life, as assessed by the King's Health Questionnaire ([@b11-cia-1-309]). The low incidence of cognitive side effects has been discussed as a benefit in the elderly. Efficacy in an elderly population has been studied by [@b13-cia-1-309], by analysis of pooled data. This included 317 patients aged 65 years or more, in one of three multicenter, randomized, double-blind, placebo controlled studies. All had OAB symptoms of more than 6-month duration. All had a 2-week washout (only if needed) and a 2-week drug-free/placebo run-in, prior to receiving once daily orally administered controlled-release darifenacin 7.5 mg (n=97) and matching placebo (n=72), or controlled-release darifenacin 15 mg (n=109) and matching placebo (n=108). At 12 weeks, both doses of darifenacin were significantly superior to placebo (p\<0.05) in improving all OAB parameters studied, confirming efficacy in an elderly population (Table [6](#t6-cia-1-309){ref-type="table"}).

Safety and tolerability
=======================

The proposed doses of darifenacin are 7.5 mg or 15 mg and in studies reporting safety and tolerability these doses been well tolerated ([@b23-cia-1-309]). Side effects are generally dose-related and of mild-to-moderate severity when they occur.

[@b10-cia-1-309] report the commonest side effects to be dry mouth (7.5 mg 20%; 15 mg 35%; placebo 8%) and constipation (7.5 mg 15%; 15 mg 21%; placebo 6%), although these resulted in low rates of discontinuation (7.5 mg 0.6%; 15 mg 2.1%; placebo 0.3%). On the other hand, CNS and cardiovascular safety were comparable with placebo. Different studies report similar findings with regard to side effects profile. [@b42-cia-1-309] in their comparison of darifenacin (15 mg QD), oxybutynin (5 mg TDS) and placebo also confirmed dry mouth and constipation as the commonest side effects of darifenacin. Dry mouth was 36.1% in the oxybutynin arm compared with 13.1% of darifenacin patients (p\<0.05) and 4% in the placebo group (p\<0.05). Rates of constipation were comparable in darifenacin (10%) and oxybutynin (8%) and significantly higher than placebo (3%, p\<0.05). Most of the side effects were mild to moderate in both groups; no patients in the darifenacin group discontinued treatment. There were no clinically relevant, treatment-emergent changes in blood pressure, pulse rate, or ECG. Dizziness and blurred vision were reported in patients taking oxybutynin.

In a comparison with tolterodine immediate-release ([@b14-cia-1-309]), dry mouth was the commonest side effect (darifenacin 7.5 mg 20.2%; darifenacin 15 mg 35%; tolterodine 26.9%; placebo 8%) in all groups. Constipation (darifenacin 7.5 mg 14.8%; darifenacin 15 mg 21%; tolterodine 10.3%; placebo 5.4%) and dyspepsia (darifenacin 7.5 mg 1.8%; darifenacin 15 mg 7.5%; tolterodine 7.6%; placebo 1.5%) were also reported. Dizziness and somnolence were reported, but the numbers were very small and no significant differences were detected in the different groups. All reported side effects are transient and tolerable. Even though constipation is one of the commonest side effects, the use of laxatives and stool softeners is low and comparable with their use in the placebo groups. Treatment-related adverse events infrequently lead to withdrawal ([@b35-cia-1-309]). Studies to date have excluded patients with hepatic disease ([@b16-cia-1-309]) in keeping with the nature of the metabolism of darifenacin. However, pharmacokinetic analyses have shown a 4.7-fold increase in drug concentrations with moderate hepatic impairment ([@b12-cia-1-309]). If being used, dose adjustment of darifenacin would be necessary in this group of patients. No clinically significant change in dose concentrations arose as a result of mild hepatic impairment, or renal impairment of varying degrees ([@b12-cia-1-309]), and so no dose adjustment is necessary.

Patient perspectives
====================

Urinary incontinence is an important contributor to the complications and economic cost of OAB for both community-dwelling and institutionalized elderly individuals. Many patients with OAB do not seek treatment because of embarrassment, fear of surgery, or the misperceptions that the problem is untreatable, or is a normal and inevitable consequence of aging. Nonpharmacological therapies improve bladder control by modifying lifestyle and behavior to prevent urine loss. This requires patient and caregiver motivation and can be time consuming. However optimal results may be obtained by combining these strategies with pharmacotherapy or by means of pharmacotherapy alone. Important considerations for elderly patients include tolerability, absence of drug interactions, and the availability of a range of dosages to tailor treatment to individual patients. As demonstrated in this review of literature, darifenacin favorably fulfills these criteria. These results are supported by significant improvements in quality of life, which have paralleled the overactive bladder symptom reductions ([@b17-cia-1-309]; [@b11-cia-1-309]). Both fixed and flexible darifenacin dosing regimens produce these beneficial effects, which extend to the more vulnerable population of older patients.

There may also be a place for incorporating patient-initiated dose adjustment into the protocol ([@b33-cia-1-309], [@b34-cia-1-309]). The primary care physician can then effectively manage adverse events associated with OAB without compromising efficacy. Given some control in the process, patients are willing to tolerate certain side effects in exchange for symptom relief.

Conclusion
==========

Evidence would suggest that darifenacin is an antimuscarinic drug particularly useful in the elderly population and therefore a useful addition to the current range of medications available on the market. Being an M~3~-specific antagonist, it is part of an important advance in the development of drugs for the treatment of OAB. Data from clinical trials have shown that darifenacin is efficacious and well tolerated in addition to providing improvements in lower urinary tract symptoms with minimal CNS side effects. It also results in significant improvements in quality of life scores. The dosage of drug also represents a compromise between efficacy and tolerability, and thus, it is important, particularly in the clinical setting, to have a range of doses that may then be tailored to patients' individual needs. Darifenacin has been compared with immediate-release tolterodine, and further studies are warranted to compare the drug with the newer QD preparations of both oxybutynin and tolterodine to examine whether the theoretical advantages of an M~3~-specific antagonist translate into clinical practice. Compliance with medical therapy remains a significant problem in the treatment of the overactive bladder. When selecting an antimuscarinic agent for the management of an elderly patient presenting with OAB, in addition to considering evidence of clinical efficacy and tolerability, issues of safety specific to an older population should be borne in mind. In particular, the likelihood of detrimental CNS effects should be considered, including cognitive impairment and sleep disturbances, secondary to anticholinergic load. Oxybutynin and tolterodine have both been associated with cognitive adverse events and effects on sleep architecture and quality. In contrast, darifenacin does not appear to be associated with cognitive adverse events and does not negatively affect sleep architecture or quality though it is just as if not more efficacious ([@b19-cia-1-309]). Darifenacin in the treatment of the OAB represents a pharmacological advance as one of a new type and class of drug.

This new addition to the armamentarium available for the management of OAB is welcome to both clinician and patient alike, and the evidence so far would suggest that darifenacin should have a major effect in this difficult-to-manage condition.

###### 

Distribution of muscarinic receptors

  Subtypes   Distribution
  ---------- ----------------------------------------------------------
  M~1~       Brain (cortex, hippocampus), sympathetic ganglia, glands
  M~2~       Heart, smooth muscle, hindbrain
  M~3~       Smooth muscle, glands, brain
  M~4~       Brain (forebrain, striatum)
  M~5~       Brain (substantia nigra), eye

###### 

Affinity (pKi) of antimuscarinic compounds for the human recombinant receptor subtypes M~1~-- M~5~ ([@b3-cia-1-309]) (Mean)

                **M~1~**   **M~2~**   **M~3~**   **M~4~**   **M~5~**
  ------------- ---------- ---------- ---------- ---------- ----------
  Darifenacin   8.2        7.4        9.1        7.3        8.0
  Oxybutynin    8.7        7.8        8.9        8.0        7.4
  Tolteridine   8.8        8.0        8.5        7.7        8.0
  Propiverine   6.6        5.4        6.4        6.0        6.5
  Trospium      9.1        9.2        9.3        9.0        8.6

###### 

Comparison of M~3~:M~1~ selectivity of the antimuscarinic compounds ([@b25-cia-1-309])

                **M~3~ versus M~1~**                           **P**
  ------------- ---------------------------------------------- ---------
  Darifenacin   9.3                                            \<0.001
  Tolteridine   0.6[a](#tfn1-cia-1-309){ref-type="table-fn"}   \<0.05
  Oxybutynin    1.5[b](#tfn2-cia-1-309){ref-type="table-fn"}   \<0.05
  Propiverine   0.6[a](#tfn1-cia-1-309){ref-type="table-fn"}   \<0.05
  Trospium      1.5                                            NS

**Notes:** ^a^Significant selectivity for M~1~, but unlikely to be biologically significant;

Significant, but unlikely to be biologically relevant.

###### 

Outcomes comparing darifenacin or matched placebo after 12 weeks of treatment ([@b10-cia-1-309])

                                                  **Darifenacin(%) (7.5 mg QD)**                            **Placebo (%)**   **Darifenacin(%) (15 mg QD)**                              **Placebo (%)**
  ----------------------------------------------- --------------------------------------------------------- ----------------- ---------------------------------------------------------- -----------------
  Incontinence episodes/week                      −8.8(−68.4)[\*](#tfn4-cia-1-309){ref-type="table-fn"}     −7(−53.8)         −10.6(−76.8)[\*\*](#tfn5-cia-1-309){ref-type="table-fn"}   7.5 (−58.3)
  Incontinence episodes resulting in pad change   −4(−77.1)                                                 −2(−47.7)         −4.8(−78.6)[\*\*](#tfn5-cia-1-309){ref-type="table-fn"}    −2.7(−55.1)
  Frequency of urgency/day                        −2(−29)[\*\*](#tfn5-cia-1-309){ref-type="table-fn"}       −1(−14.3)         −2.3(−29)[\*\*](#tfn5-cia-1-309){ref-type="table-fn"}      −1.2(−16.7)
  Micturition Frequency/day                       −1.6(−16.6)[\*\*](#tfn5-cia-1-309){ref-type="table-fn"}   −0.9(−9.1)        −1.9(−17.4)[\*\*](#tfn5-cia-1-309){ref-type="table-fn"}    −1(−9.9)
  Bladder capacity (mean vol void:ml)             15.4(9.6)[\*](#tfn4-cia-1-309){ref-type="table-fn"}       7.6(4.9)          26.9(17.5)[\*\*](#tfn5-cia-1-309){ref-type="table-fn"}     5.9(3.9)
  Severity of urgency                             −7.8(−14.2)[\*\*](#tfn5-cia-1-309){ref-type="table-fn"}   −4.2(−7.8)        −9.3(−16.1)[\*\*](#tfn5-cia-1-309){ref-type="table-fn"}    −4.5(−8)

**Notes:** Results expressed as median (%) change from baseline, at week 12;

p\<0.01;

p\<0.001 (Wilcoxon rank-sum test).

###### 

Comparison of 2 weeks treatment outcomes of darifenacin, oxybutynin, or placebo ([@b42-cia-1-309])

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                              **Darifenacin**\                                  **Oxybutynin**\                                  **Placebo**\
                                                                              **(n=58)**\                                       **(n=58)**\                                      \
                                                                              **15 mg QD**                                      **5 mg TDS**                                     **(n=58)**
  --------------------------------------------------------------------------- ------------------------------------------------- ------------------------------------------------ --------------
  Micturition/day                                                             9.33                                              9.24                                             9.62

  Incontinence episodes/week                                                  10.93[\*](#tfn7-cia-1-309){ref-type="table-fn"}   9.45[\*](#tfn7-cia-1-309){ref-type="table-fn"}   14.64

  Urgency episodes/day                                                        7.95[\*](#tfn7-cia-1-309){ref-type="table-fn"}    8.12[\*](#tfn7-cia-1-309){ref-type="table-fn"}   8.71

  Severity of urgency episode^[\*\*](#tfn8-cia-1-309){ref-type="table-fn"}^   1.93[\*](#tfn7-cia-1-309){ref-type="table-fn"}    1.89[\*](#tfn7-cia-1-309){ref-type="table-fn"}   2.03
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Evaluable patients (n=58). Values shown are means adjusted for sequence and period from the crossover analysis of variance;

p\<0.05 vs placebo, accounting from multiplicity by least significant difference method;

1=mild, 2=moderate, 3=severe.

**Abbreviations:** QD, once daily; TDS, three times daily

###### 

Outcome following 12 weeks of treatment in elderly patients ([@b13-cia-1-309])

  **Efficacy parameters**                  **Darifenicin (7.5 mg QD)**   **Placebo**   **Darifenacin (15 mg QD)**   **Placebo**
  ---------------------------------------- ----------------------------- ------------- ---------------------------- -------------
  Micturitions/day                         −1.8(−18.2)                   −0.6(−6.5)    −1.8(−16.9)                  −1.0(−9.1)
  Incontinence episodes/week               −11.2(−66.7)                  −4.8(−34.8)   −10.8(−75.9)                 −6.8(−44.8)
  Number of urgency episodes/day           −2.1(−25.7)                   −0.6(−6.6)    −2.4(−25.7)                  −0.8(−10.4)
  Bladder capacity (mean vol voided mls)   14(10.4)                      2(1.3)        27(18.0)                     2(1.3)

**Notes:** Results expressed as median (%) change from baseline to week 12; p\<0.05 in improving all four efficacy parameters (Wilcoxon rank-sum test, stratified by study).

**Abbreviations:** QD, once daily.
